ARIH1 and prostate carcinoma: Interestingly, ARIH1 missense mutations are found in 4% of non-small cell lung cancer patients (n = 75)56, 3.25% of prostate cancer patients (n = 154)57, and 5.13% of cutaneous squamous cell carcinoma patients (n = 39)58.